A Multicenter, Prospective, Non-interventional Study of Maintenance Avastin (Bevacizumab) Following Induction Treatment With Platinum Doublet Plus Avastin in Patients With Advanced Lung Adenocarcinoma
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 06 Oct 2017
At a glance
- Drugs Bevacizumab (Primary)
- Indications Adenocarcinoma; Lung cancer
- Focus Therapeutic Use
- Sponsors Roche
- 02 Oct 2017 Status changed from recruiting to active, no longer recruiting.
- 31 Jul 2015 Planned End Date changed from 1 May 2018 to 1 Oct 2017 as reported by ClinicalTrials.gov.
- 31 Jul 2015 Planned primary completion date changed from 1 May 2018 to 1 Oct 2017 as reported by ClinicalTrials.gov.